Laura Soucek
#112,114
Most Influential Person Now
Researcher
Laura Soucek's AcademicInfluence.com Rankings
Laura Soucekmedical Degrees
Medical
#3254
World Rank
#3716
Historical Rank
Oncology
#229
World Rank
#237
Historical Rank
Laura Soucekbiology Degrees
Biology
#8241
World Rank
#11285
Historical Rank
Molecular Biology
#2234
World Rank
#2268
Historical Rank
Download Badge
Medical Biology
Laura Soucek's Degrees
- PhD Molecular Biology University of Barcelona
Why Is Laura Soucek Influential?
(Suggest an Edit or Addition)According to Wikipedia, Laura Soucek is a Group Leader at VHIO , Research Professor at ICREA, and CEO of Peptomyc S.L. She works on the Myc oncoprotein, the deregulation of which occurs during almost all cancers. Soucek has designed a dominant negative variant, Omomyc, which allows her to investigate the benefits of inhibiting Myc in cancer.
Laura Soucek's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Modelling Myc inhibition as a cancer therapy (2008) (750)
- Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors (2007) (489)
- Drugging the 'undruggable' cancer targets (2017) (477)
- Interrogating open issues in cancer precision medicine with patient-derived xenografts (2017) (462)
- Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology. (2012) (311)
- Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. (2013) (256)
- Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead (2015) (219)
- Strategies to Inhibit Myc and Their Clinical Applicability (2017) (206)
- Temporal dissection of p53 function in vitro and in vivo (2005) (189)
- c-Myc recruits P-TEFb for transcription, cellular proliferation and apoptosis (2003) (185)
- The ups and downs of Myc biology. (2010) (170)
- Endogenous Myc maintains the tumor microenvironment. (2011) (160)
- Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis (2014) (152)
- Design and properties of a Myc derivative that efficiently homodimerizes (1998) (148)
- Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis. (2002) (142)
- Making decisions through Myc (2001) (129)
- Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy (2019) (117)
- The Action Mechanism of the Myc Inhibitor Termed Omomyc May Give Clues on How to Target Myc for Cancer Therapy (2011) (95)
- The effect of environmental chemicals on the tumor microenvironment. (2015) (93)
- Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma. (2015) (92)
- Reversible kinetic analysis of Myc targets in vivo provides novel insights into Myc-mediated tumorigenesis. (2006) (87)
- Myc instructs and maintains pancreatic adenocarcinoma phenotype (2019) (82)
- Tumor microenvironment: becoming sick of Myc (2011) (73)
- Omomyc expression in skin prevents Myc-induced papillomatosis (2004) (63)
- Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc (2020) (56)
- Acute Overexpression of Myc in Intestinal Epithelium Recapitulates Some but Not All the Changes Elicited by Wnt/β-Catenin Pathway Activation (2009) (55)
- Modeling pharmacological inhibition of mast cell degranulation as a therapy for insulinoma. (2011) (52)
- Bcl-xL gain of function and p19 ARF loss of function cooperate oncogenically with Myc in vivo by distinct mechanisms. (2006) (52)
- MYC, MYCL, and MYCN as therapeutic targets in lung cancer (2020) (48)
- Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation (2016) (48)
- Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead (2015) (45)
- Myc-Is this the oncogene from Hell? (2002) (41)
- Inhibition of MYC attenuates tumor cell self‐renewal and promotes senescence in SMARCB1‐deficient Group 2 atypical teratoid rhabdoid tumors to suppress tumor growth in vivo (2019) (36)
- Structural and Biophysical Insights into the Function of the Intrinsically Disordered Myc Oncoprotein (2020) (36)
- Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies (2019) (28)
- NGF‐dependent and tissue‐specific transcription of vgf is regulated by a CREB–p300 and bHLH factor interaction (2002) (27)
- Erratum: Interrogating open issues in cancer medicine with patient-derived xenografts (2017) (26)
- Inhibition of Myc effectively targets KRAS mutation-positive lung cancer expressing high levels of Myc. (2010) (26)
- Tamoxifen administration to mice. (2015) (24)
- The long journey to bring a Myc inhibitor to the clinic (2021) (22)
- Epigenetic SMAD3 repression in tumor-associated fibroblasts impairs fibrosis and response to the antifibrotic drug nintedanib in lung squamous cell carcinoma. (2019) (18)
- Pancreatic cancer heterogeneity and response to Mek inhibition (2017) (18)
- Ibrutinib repurposing: from B-cell malignancies to solid tumors (2016) (17)
- Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts (2021) (12)
- Myc and Ras, the Bonnie and Clyde of immune evasion. (2018) (11)
- Integrated requirement of non‐specific and sequence‐specific DNA binding in Myc‐driven transcription (2021) (9)
- Integrated requirement of non-specific and sequence-specific DNA binding in MYC-driven transcription (2020) (8)
- BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC (2018) (8)
- The estrogen receptor fusion system in mouse models: a reversible switch. (2015) (8)
- Biophysical characterization of the b-HLH-LZ of ΔMax, an alternatively spliced isoform of Max found in tumor cells: Towards the validation of a tumor suppressor role for the Max homodimers (2017) (7)
- The Myc Gene (2013) (5)
- MYC inhibitors in multiple myeloma (2021) (4)
- Thinking beyond the tumor cell: Nf1 haploinsufficiency in the tumor environment (2002) (4)
- Finding MYCure (2019) (4)
- The Wnt signaling receptor Fzd9 is essential for Myc-driven tumorigenesis in pancreatic islets (2021) (3)
- MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding (2022) (2)
- The Myc world within reach. (2013) (2)
- Author Correction: Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts (2021) (2)
- 916 Modeling Pharmacological Inhibition of Bruton's Tyrosine Kinase (BTK) as a Therapy for Insulinoma and Pancreatic Ductal Adenocarcinoma (2012) (1)
- Mouse Models in Personalized Cancer Medicine (2017) (1)
- Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma. (2021) (1)
- Abstract A52: Myc is required for maintenance of KRasG12D-driven pancreatic cancer and its associated microenvironment (2015) (1)
- The ER Fusion System in Mouse Models: A Reversible Switch (2019) (1)
- Abstract 3435: Identification of potential biomarkers of response to OMO-103, a first-in-modality pan-MYC inhibitor, in patients with advanced solid tumors (2023) (0)
- Live or Die: Choice Mechanisms in Stressed Cells (2015) (0)
- Abstract 2167: Preclinical validation of an Omomyc cell-penetrating peptide as a viable anti-Myc therapy (2017) (0)
- A spotlight on cancer researchers in Spain: new paradigms and disruptive ideas (2019) (0)
- S02-05 Targeting tumor suppressor pathways to treat cancer (2009) (0)
- tumor-associated macrophage biology Role of c-MYC in alternative activation of human macrophages and (2014) (0)
- Characterization of KRAS-driven NSCLC cell lines with diverse mutational landscape and assessment of their response to MYC inhibition (2022) (0)
- Abstract LB-034: Myc instructs and maintains pancreatic adenocarcinoma phenotype (2019) (0)
- Abstract 396: Ibrutinib exerts potent antifibrotic activity in a mouse model of pancreatic adenocarcinoma (2015) (0)
- Abstract PR10: Preclinical validation of Myc inhibition by a new generation of Omomyc-based cell penetrating peptides (2015) (0)
- 773: A novel pharmacological approach to inhibit Myc in cancer (2014) (0)
- MYC inhibition by Omomyc as a therapeutic strategy for (KRAS-mutated) colorectal cancer (2022) (0)
- OA08.07 Aberrant Epigenetic SMAD3 Signaling in Tumor-Associated Fibroblasts Modulates Fibrosis and Response to Nintedanib in NSCLC (2019) (0)
- Abstract 4956: Pharmacological inhibition of Bruton's Tyrosine Kinase (BTK) as a therapy for insulinoma and pancreatic ductal adenocarcinoma. (2013) (0)
- Abstract 1085: MYC inhibition is a potent therapy against glioma and induces mitotic crisis in cancer cells. (2013) (0)
- Myc Inhibition as a Therapeutic Strategy Against Glioma: a Role for Myc in Proficient Mitosis (2014) (0)
- Abstract B23: Pushing Myc inhibition towards the clinic by direct delivery of cell-penetrating peptides (2015) (0)
- Abstract 3849: Mast cell inhibition by Btk inhibitor PCI-32765 as a potential cancer therapy (2010) (0)
- Abstract 1823: Translating Myc inhibition to the clinic in metastatic breast cancer (2020) (0)
- MYC inhibition by Omomyc unveils a prognostic gene signature in Melanoma (2022) (0)
- Abstract 1225: Aberrant SMAD3 signaling in tumor-associated fibroblasts modulates fibrosis and response to the anti-fibrotic drug nintedanib in non-small cell lung cancer (2019) (0)
- Abstract B09: Myc is required for maintenance of KRasG12D-driven pancreatic cancer and its associated microenvironment (2015) (0)
- Targeting MYC-driven lymphoma: lessons learned and future directions (2023) (0)
- Going for a “KDIP” in colorectal cancer treatment (2022) (0)
- Procédé et compositions de traitement du cancer (2013) (0)
- Abstract 1685: The EurOPDX Research Infrastructure: Supporting European and worldwide cancer research with patient-derived xenografts (2020) (0)
- Abstract 3956: Omomyc-based cell-penetrating peptides: From proof of concept to a clinically viable anti-Myc therapy (2018) (0)
- An "-omycs" Toolbox to Work with MYC. (2021) (0)
- Omomyc downregulates MYC transcriptional signature in preclinical models of solid tumours and shows long half-life in tumour tissue (2022) (0)
- THE THERAPEUTIC IMPACT OF MYC INHIBITION IN RAS-INDUCED GLIOMA (2010) (0)
- Editorial overview: Peptides in cancer. (2019) (0)
- Dose escalation study of OMO-103, a first in class Pan-MYC-Inhibitor in patients (pts) with advanced solid tumors (2022) (0)
- Acute Overexpression of Myc in Intestinal Epithelium Recapitulates Some but Not All the Changes Elicited by Wnt/ (cid:2) -Catenin Pathway Activation (cid:1) (2009) (0)
- Abstract 469: Mast cell inhibition by the BTK inhibitor PCI-32765 as a potential therapy in pancreatic cancer (2011) (0)
- Minireview Making decisions through Myc (2001) (0)
- 749 Myc – a Non Redundant Function in Cancer (2012) (0)
- Omomyc mini-protein can be directly and continuously delivered to the brain to prevent glioblastoma in patient-derived xenograft mouse models (2022) (0)
- 751 MYC Inhibition as a Therapeutic Strategy in Glioma (2012) (0)
- Abstract 3351: Myc inhibition by Omomyc impairs melanoma growth and progression through genome-wide gene expression reprogramming (2018) (0)
- IA16 A New Generation of Anti-Myc Mini-Proteins as Potential Therapy for NSCLC (2020) (0)
- Abstract 2923: Preclinical validation of Omomyc cell-penetrating peptides as a viable in vivo anti-Myc therapy (2016) (0)
- Abstract B16: Targeting Myc in metastatic breast cancer by Omomyc: From proof of principle to pharmacologic approach (2018) (0)
- Abstract 2645: Preclinical validation of Myc inhibition by a new generation of Omomyc-based inhibitors (2015) (0)
- Bile salt supplementation acts via c-Myc to promote intestinal epithelial proliferation after LPS-induced injury (2011) (0)
- Tumor microenvironment: becoming sick of Myc (2011) (0)
- MYC inhibition by OMO-103 induces immune cell recruitment in preclinical models of NSCLC and modulates the cytokine and chemokine profiles of Phase I patients showing stable disease (2022) (0)
- Reducing MYC's transcriptional footprint unveils a good prognostic gene signature in melanoma (2023) (0)
- Pharmacokinetic Analysis of Omomyc Shows Lasting Structural Integrity and Long Terminal Half-Life in Tumor Tissue (2023) (0)
- Omomyc as a novel therapeutic strategy against metastatic triplenegative breast cancer, alone and in combination with the standard of care (2022) (0)
This paper list is powered by the following services:
Other Resources About Laura Soucek
What Schools Are Affiliated With Laura Soucek?
Laura Soucek is affiliated with the following schools:
